[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kairos Pharma Ltd (KAPA)

Kairos Pharma Ltd (KAPA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,935
  • Shares Outstanding, K 21,411
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,450 K
  • EBIT $ -6 M
  • EBITDA $ -3 M
  • 60-Month Beta 1.51
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.59
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.30
  • Most Recent Earnings $-0.07 on 03/31/26
  • Next Earnings Date 05/13/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.08
  • Number of Estimates 1
  • High Estimate $-0.08
  • Low Estimate $-0.08
  • Prior Year $-0.08
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4300 +13.95%
on 05/13/26
0.7100 -30.99%
on 04/22/26
-0.1095 (-18.27%)
since 04/14/26
3-Month
0.4300 +13.95%
on 05/13/26
0.7500 -34.67%
on 02/26/26
-0.1080 (-18.06%)
since 02/13/26
52-Week
0.4000 +22.50%
on 06/03/25
2.1100 -76.78%
on 09/08/25
-0.1300 (-20.97%)
since 05/14/25

Most Recent Stories

More News
Kairos Pharma Receives GHP Magazine’s Healthcare & Pharmaceutical Award

Company selected for the Leaders in Drug Resistance Development award

KAPA : 0.4900 (+5.60%)
Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI

Los Angeles, California--(Newsfile Corp. - May 13, 2026) - Kairos Pharma, Ltd. (NYSE American: KAPA) announced today that it will be participating in the 16th Annual LD Micro Invitational at the Luxe Sunset...

KAPA : 0.4900 (+5.60%)
Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings

Kairos Pharma, Ltd. (NYSE American: KAPA) , a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that its Annual Meeting of Shareholders will be held virtually...

KAPA : 0.4900 (+5.60%)
Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation

Company selected as an Emerald honoree for Innovator of Biotech Solutions

KAPA : 0.4900 (+5.60%)
Kairos Pharma Investor News: Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPA

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Kairos Pharma, Ltd. (NYSE American: KAPA)...

KAPA : 0.4900 (+5.60%)
Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPA

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Kairos Pharma, Ltd. (NYSE American: KAPA) resulting from allegations...

KAPA : 0.4900 (+5.60%)
Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics

The next‑generation, AI‑designed pan‑EGFR inhibitor for EGFR‑mutant lung cancer significantly expands the Company’s oncology pipeline Targeting a $16.2 Billion Market Opportunity

KAPA : 0.4900 (+5.60%)
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics

Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung...

KAPA : 0.4900 (+5.60%)
Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference

CSO Neil Bhowmick to deliver company presentation and will be available for investor meetings

KAPA : 0.4900 (+5.60%)
Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer

Company recognized for advancing ENV‑105, a first‑in‑class resistance‑modulating antibody for metastatic castration‑resistant prostate cancer

KAPA : 0.4900 (+5.60%)

Business Summary

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company. It focused on developing a diversified pipeline of cutting-edge oncology therapeutics born from structural biology to reverse cancer drug resistance and the inhibitory effects of cancer on the immune system. Kairos Pharma Ltd. is based...

See More

Key Turning Points

3rd Resistance Point 0.5767
2nd Resistance Point 0.5433
1st Resistance Point 0.5167
Last Price 0.4900
1st Support Level 0.4567
2nd Support Level 0.4233
3rd Support Level 0.3967

See More

52-Week High 2.1100
Fibonacci 61.8% 1.4568
Fibonacci 50% 1.2550
Fibonacci 38.2% 1.0532
Last Price 0.4900
52-Week Low 0.4000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.